Cytek Biosciences Inc (CTKB)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021
Total current assets	US$ in thousands	392,060	422,315	424,821	425,622	454,020	443,859	443,270	439,112	431,733	439,826	216,938
Total current liabilities	US$ in thousands	56,226	58,693	53,591	56,517	49,040	41,494	42,350	42,803	33,181	30,014	28,165
Current ratio		6.97	7.20	7.93	7.53	9.26	10.70	10.47	10.26	13.01	14.65	7.70

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $392,060K ÷ $56,226K
= 6.97

The current ratio of Cytek Biosciences Inc has been consistently high over the past several quarters, ranging from 6.97 to 14.65. The company's current assets have been significantly higher than its current liabilities, indicating a strong ability to meet its short-term obligations.

A current ratio above 1.0 is generally considered healthy, as it suggests the company has more than enough short-term assets to cover its short-term liabilities. Cytek's current ratio has been well above this threshold in all the reported periods, which is a positive sign of financial health and liquidity.

The fluctuation in the current ratio over the periods could be due to changes in the composition of current assets and liabilities or variations in the company's operating cycle. However, the overall trend indicates that Cytek has maintained a robust liquidity position and is well-positioned to meet its near-term financial obligations.

It is important for investors and stakeholders to monitor the current ratio along with other financial metrics to assess the company's overall financial stability and liquidity position.